These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. Sadovnik I; Hoelbl-Kovacic A; Herrmann H; Eisenwort G; Cerny-Reiterer S; Warsch W; Hoermann G; Greiner G; Blatt K; Peter B; Stefanzl G; Berger D; Bilban M; Herndlhofer S; Sill H; Sperr WR; Streubel B; Mannhalter C; Holyoake TL; Sexl V; Valent P Clin Cancer Res; 2016 Apr; 22(8):2051-61. PubMed ID: 26607600 [TBL] [Abstract][Full Text] [Related]
27. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. Jiang X; Saw KM; Eaves A; Eaves C J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736 [TBL] [Abstract][Full Text] [Related]
28. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors. Danisz K; Blasiak J Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759 [TBL] [Abstract][Full Text] [Related]
29. Selective elimination of leukemia stem cells: hitting a moving target. Crews LA; Jamieson CH Cancer Lett; 2013 Sep; 338(1):15-22. PubMed ID: 22906415 [TBL] [Abstract][Full Text] [Related]
30. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation. Wodarz D Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666 [TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors. Costa A; Scalzulli E; Carmosino I; Ielo C; Bisegna ML; Martelli M; Breccia M Expert Opin Pharmacother; 2024 Feb; 25(2):189-202. PubMed ID: 38488824 [TBL] [Abstract][Full Text] [Related]
32. Expression of CD25 on leukemic stem cells in BCR-ABL1 Sadovnik I; Herrmann H; Eisenwort G; Blatt K; Hoermann G; Mueller N; Sperr WR; Valent P Exp Hematol; 2017 Jul; 51():17-24. PubMed ID: 28457753 [TBL] [Abstract][Full Text] [Related]
33. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. Erba HP Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137 [TBL] [Abstract][Full Text] [Related]
34. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
35. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973 [TBL] [Abstract][Full Text] [Related]
36. Residual Peripheral Blood CD26 Bocchia M; Sicuranza A; Abruzzese E; Iurlo A; Sirianni S; Gozzini A; Galimberti S; Aprile L; Martino B; Pregno P; Sorà F; Alunni G; Fava C; Castagnetti F; Puccetti L; Breccia M; Cattaneo D; Defina M; Mulas O; Baratè C; Caocci G; Sica S; Gozzetti A; Luciano L; Crugnola M; Annunziata M; Tiribelli M; Pacelli P; Ferrigno I; Usala E; Sgherza N; Rosti G; Bosi A; Raspadori D Front Oncol; 2018; 8():194. PubMed ID: 29900128 [TBL] [Abstract][Full Text] [Related]
37. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673 [TBL] [Abstract][Full Text] [Related]
39. [Tyrosine kinase inhibitors for the treatment of CML]. Heim D Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455 [TBL] [Abstract][Full Text] [Related]
40. [Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences]. Hokland P; Ommen HB; Nyvold CG; Stentoft J; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M Ugeskr Laeger; 2009 Jan; 171(4):232-5. PubMed ID: 19174038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]